Corrigendum to "Silencing adenosine A2a receptor enhances dendritic cell-based cancer immunotherapy" [Nanomedicine Nanotechnol Biol Med 29 (2020) 102240]

Affiliations

• ¹ Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
• ² Department of Chemical and Materials Engineering, The University of Alabama in Huntsville, AL, USA.
• ³ Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
• ⁴ Department of Clinical Biochemistry, Islamic Azad University, Falavarjan Branch, Isfahan, Iran.
• ⁵ Department of Biochemistry, Faculty of Biological Sciences, University of Tarbiat Modares, Tehran, Iran.
• ⁶ Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
• ⁷ Nanotechnology Research Centre, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
• ⁸ Immunogenetic Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
• ⁹ Bioclinicum, Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden; The Persian Gulf Marine Biotechnology Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, Iran.
• ¹⁰ Department of Oncology, Cross Cancer Institute, The University of Alberta, Edmonton, Alberta, Canada.
• ¹¹ Cellular and Molecular Research Center, Yasuj University of Medical Sciences, Yasuj, Iran.
• ¹² Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: jadidif@tbzmed.ac.ir.